GenoFocus Inc (187420) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GenoFocus Inc (187420) has a cash flow conversion efficiency ratio of -0.015x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-821.53 Million ≈ $-556.74K USD) by net assets (₩53.43 Billion ≈ $36.21 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GenoFocus Inc (187420) liquidity interval to measure how many days the company can operate on defensive assets alone.
GenoFocus Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how GenoFocus Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
GenoFocus Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GenoFocus Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Iep Invest
BR:IEP
|
-0.003x |
|
IFirma SA
WAR:IFI
|
0.126x |
|
Sam Jung Pulp
KO:009770
|
0.006x |
|
Memscap Regpt
PA:MEMS
|
0.048x |
|
Openbase Inc
KQ:049480
|
0.018x |
|
Sýn hf
IC:SYN
|
0.105x |
|
Digital Multimedia Technology Co.Ltd
KQ:134580
|
0.112x |
|
Orbis AG
XETRA:OBS
|
0.202x |
Annual Cash Flow Conversion Efficiency for GenoFocus Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of GenoFocus Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see GenoFocus Inc (187420) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩54.75 Billion ≈ $37.10 Million |
₩3.50 Billion ≈ $2.37 Million |
0.064x | -47.00% |
| 2024-12-31 | ₩23.77 Billion ≈ $16.11 Million |
₩2.87 Billion ≈ $1.95 Million |
0.121x | +166.11% |
| 2023-12-31 | ₩26.36 Billion ≈ $17.87 Million |
₩-4.82 Billion ≈ $-3.26 Million |
-0.183x | +7.37% |
| 2022-12-31 | ₩23.89 Billion ≈ $16.19 Million |
₩-4.71 Billion ≈ $-3.19 Million |
-0.197x | -191.01% |
| 2021-12-31 | ₩35.28 Billion ≈ $23.91 Million |
₩-2.39 Billion ≈ $-1.62 Million |
-0.068x | -9.88% |
| 2020-12-31 | ₩39.77 Billion ≈ $26.95 Million |
₩-2.45 Billion ≈ $-1.66 Million |
-0.062x | -1818.94% |
| 2019-12-31 | ₩52.12 Billion ≈ $35.32 Million |
₩-167.50 Million ≈ $-113.51K |
-0.003x | -112.37% |
| 2018-12-31 | ₩60.21 Billion ≈ $40.80 Million |
₩1.56 Billion ≈ $1.06 Million |
0.026x | +22.28% |
| 2017-12-31 | ₩64.22 Billion ≈ $43.52 Million |
₩1.36 Billion ≈ $924.25K |
0.021x | +157.26% |
| 2016-12-31 | ₩62.52 Billion ≈ $42.37 Million |
₩516.09 Million ≈ $349.74K |
0.008x | -91.38% |
| 2015-12-31 | ₩29.79 Billion ≈ $20.19 Million |
₩2.85 Billion ≈ $1.93 Million |
0.096x | +423.17% |
| 2014-12-31 | ₩9.66 Billion ≈ $6.55 Million |
₩-286.45 Million ≈ $-194.12K |
-0.030x | -- |
About GenoFocus Inc
HLB Genex, Inc. engages in the research and development, production, import/export, and sale of enzymes and fermentation products in South Korea and internationally. Its industrial special enzyme products include lactase; catalase for use in semiconductor industry; and proteinase K for molecular diagnostics and genetic engineering experiments, as well as bio-health care ingredients comprise N-phy… Read more